

# ASX Announcement

## 13 November 2019



NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

FOR IMMEDIATE RELEASE

13 November 2019

### SUCCESSFUL COMPLETION OF RETAIL ENTITLEMENT OFFER

On Monday, 21 October 2019 Cogstate Limited (**Cogstate**) announced a fully underwritten 1 for 10 accelerated pro-rata non-renounceable entitlement offer of new shares (**Entitlement Offer**) to raise approximately A\$4 million. The institutional component of the Entitlement Offer (**Institutional Entitlement Offer**) was successfully completed on Monday, 21 October 2019.

Cogstate today announces successful completion of the retail component of the Entitlement Offer (**Retail Entitlement Offer**) which closed at 5.00pm on Friday, 8 November 2019.

Under the Retail Entitlement Offer, eligible retail shareholders applied for approximately A\$771,134 pursuant to their entitlements (representing a take up rate of approximately 69%). Applications under the top-up facility were A\$210,762 after scale back in accordance with the terms of the Entitlement Offer, increasing the total take-up from eligible Cogstate shareholders to A\$981,896 (representing a total take up take of approximately 87.5%). The shortfall stock will be allotted to sub-underwriters of the Entitlement Offer.

Completion of the Retail Entitlement Offer represents the final stage of Cogstate's approximately A\$4 million equity raising. Total gross proceeds from the Entitlement Offer raised approximately A\$4 million.

The new shares to be issued under the Retail Entitlement Offer will rank equally with existing Cogstate ordinary shares in all respects from the date of their issue. Settlement of the Retail Entitlement Offer is scheduled to take place on Thursday, 14 November 2019. New shares are expected to be issued on Friday, 15 November 2019 and commence trading on the ASX on Monday, 18 November 2019.

#### For further information contact:

Brad O'Connor

Cogstate Chief Executive Officer

[boconnor@cogstate.com](mailto:boconnor@cogstate.com)

#### About Cogstate

Cogstate Ltd (ASX:CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific

consulting. For nearly 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. For more information, please visit [www.cogstate.com](http://www.cogstate.com).

## **NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

*This release is for information purposes only and is not financial product or investment advice or a recommendation to acquire Cogstate shares (nor does it or will it form any part of any contract to acquire Cogstate shares). The information in this release is in summary form and does not contain all the information necessary to fully evaluate the Entitlement Offer or any potential investment in Cogstate. It should be read in conjunction with Cogstate's other periodic and continuous disclosure announcements lodged with ASX. This release has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives and financial situation and seek legal, financial and taxation advice.*

*This release may not be distributed or released in the United States. This release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to any person who is acting for the account or benefit of any person in the United States (to the extent such person is acting for the account or benefit of a person in the United States), or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal. None of the Entitlements nor the New Shares and Additional New Shares have been, or will be, registered under the U.S. Securities Act of 1933 (Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, none of the Entitlements nor the New Shares and Additional New Shares may be offered or sold, directly or indirectly, in the United States or to any person who is acting for the account or benefit of any person in the United States (to the extent such person is acting for the account or benefit of a person in the United States), except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States.*

*All dollar values are in Australian dollars (A\$) unless otherwise stated.*